Exceptional experience in glycobiology and therapeutic antibody development
Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies. We combine expertise in glycobiology and know-how in antibody development to advance first-in-class antibody-based therapeutics for (immuno)-oncology.
Technology Platform: Cancer cells show altered glycosylation patterns compared to healthy cells making these glyco-epitopes highly interesting therapeutic targets. We have developed a target-discovery approach that enables us to identify proteins that carry an aberrant glycosylation if expressed in cancerous tissues of several indications.
Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glyco-epitopes (GlycoTargets). Based on their superior tumor-specificity, our antibodies are suitable for development in an array of different modes of action including naked antibodies, bispecifics, antibody-drug-conjugates, cellular therapies or fusion-proteins.
Glycotope was founded in Berlin. Today, the Company has ~30 employees working on the Berlin-Buch Biotech Campus on the further development of our technology and the realization of our vision.